How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Wearable Autoinjector Market
- By Device Type: Reusable Wearable Autoinjectors, Disposable Wearable Autoinjectors, Patch-based Wearable Autoinjectors
- By Therapeutic Area: Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Allergic Conditions, Diabetes
- By End User: Hospitals and Clinics, Home Healthcare Settings, Specialty Clinics
- By Drug Delivery Volume: Low Volume (up to 1 mL), Medium Volume (1-5 mL), High Volume (above 5 mL)
- By Connectivity Features: Bluetooth-enabled Autoinjectors, Non-connected Autoinjectors, Smart Autoinjectors with Dose Tracking
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Reusable Wearable Autoinjectors leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Wearable Autoinjector Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Device Type 3
Therapeutic Area 5
End User 3
Drug Delivery Volume 3
Connectivity Features 3
Companies profiled
Ypsomed AG
SHL Group
West Pharmaceutical Services Inc.
Enable Injections
Haselmeier AG
Unilife Corporation
Gerresheimer AG
Sensile Medical AG
Nemera
Owen Mumford Ltd
Vetter Pharma International GmbH
Phillips-Medisize Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Ypsomed AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →SHL Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →West Pharmaceutical Services Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Enable Injections
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Haselmeier AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Unilife Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Gerresheimer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sensile Medical AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Nemera
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Owen Mumford Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vetter Pharma International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Phillips-Medisize Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Becton
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Dickinson and Company (BD)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Medimop Medical Projects Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Bespak by Recipharm
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,649M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Reusable Wearable Autoinjectors60.4
- Disposable Wearable Autoinjectors16.7
- Patch-based Wearable Autoinjectors22.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,231M → $2,097M · 6.9%
Europe$857.9M → $1,392M · 6.2%
Asia Pacific$783.3M → $1,510M · 8.5%
Latin America$484.9M → $874.9M · 7.7%
Middle East and Africa$373.0M → $690.9M · 8.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.442026
7.462027
7.482028
7.482029
7.492030
7.502031
7.522032
7.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Ypsomed AG17.3
- SHL Group24.9
- West Pharmaceutical Services Inc.3.8
- Enable Injections10.2
- Haselmeier AG10.1
- Unilife Corporation5.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type12.9%
Therapeutic Area30.2%
End User27.0%
Drug Delivery Volume16.3%
Connectivity Features13.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe21.2
- Asia Pacific23.0
- Latin America13.3
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Ypsomed AG | 73 | 91 | 78 | 87 | 78 | 74 | 80 |
| SHL Group | 87 | 80 | 79 | 70 | 70 | 80 | 78 |
| West Pharmaceutical Services Inc. | 78 | 63 | 81 | 72 | 72 | 64 | 72 |
| Enable Injections | 77 | 57 | 59 | 82 | 69 | 69 | 69 |
| Haselmeier AG | 71 | 55 | 73 | 67 | 59 | 62 | 65 |
| Unilife Corporation | 54 | 67 | 63 | 46 | 59 | 51 | 57 |
| Gerresheimer AG | 55 | 48 | 62 | 42 | 60 | 61 | 55 |
| Sensile Medical AG | 47 | 57 | 54 | 40 | 49 | 40 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Ypsomed AG
- SHL Group
- West Pharmaceutical Services Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Ypsomed AG | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| SHL Group | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| West Pharmaceutical Services Inc. | ◐ | ◐ | ✓ | − | ✓ | ◐ |
| Enable Injections | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Haselmeier AG | ◐ | − | ◐ | − | − | ◐ |
| Unilife Corporation | ◐ | − | − | − | ◐ | ◐ |
| Gerresheimer AG | ◐ | − | ◐ | − | − | − |
| Sensile Medical AG | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Ypsomed AG80
2SHL Group78
3West Pharmaceutical Services Inc.72
4Enable Injections69
5Haselmeier AG65
6Unilife Corporation57
7Gerresheimer AG55
8Sensile Medical AG48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Ypsomed AGSHL Group
Challenger2
Strong scale, closing on the leaders.
West Pharmaceutical Services Inc.Enable Injections
Contender2
Focused players with pockets of strength.
Haselmeier AGUnilife Corporation
Niche2
Specialists in a single segment or region.
Gerresheimer AGSensile Medical AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Wearable Autoinjector Market — a $197M beachhead inside a $3.04B market.
Beachhead (SOM)$197Mobtainable near-term
Serviceable (SAM)$1.27Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Reusable Wearable Autoinjectors
Best fit — highest urgency & budget in Device Type.
Economic buyer78 fit
Disposable Wearable Autoinjectors
Strong fit — clear ROI and a fast path to value.
End user69 fit
Patch-based Wearable Autoinjectors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Wearable Autoinjector Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation14%
Closed-won5%
$17.2KCAC
$100KLTV
5.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Wearable Autoinjector Market is a durable-growth opportunity — $6.04B by 2033, compounding at 7.7%.
TAM · 2025$3.33Btoday
TAM · 2033$6.04Bforecast
CAGR7.7%2027–2033
Cumulative$41.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.04BTotal addressable market
SAM$2.28BServiceable available market
SOM$416MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.7% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.04BLarge & growingTAM by 2033 at 7.7% CAGR
$2.28BServiceable nowreachable with today’s model
$416MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.71BBear5.0% CAGR
$6.04BBase7.7% CAGR
$7.74BBull10.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Wearable Autoinjector Market — a $1.33B market by 2033. Plan: grow share from 10.4% to 16.9%.
Market size · 2033$1.33Btotal addressable
Market CAGR4.1%2027–2033
Target share16.9%from 10.4% today
Revenue ambition$225Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 16.9% | Ahead |
| Revenue | $126M | $225M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 33.1% | 40.5% | Behind |
| Customer retention | 84.8% | 92.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $27M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Wearable Autoinjector Market conversation — a $4.07B market you can size, segment and defend in minutes.
Market size · 2033$4.07Btotal opportunity
Growth7.0%CAGR to 2033
Addressable buyers953+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Ypsomed AGSHL GroupWest Pharmaceutical Services Inc.Enable InjectionsHaselmeier AGUnilife CorporationGerresheimer AGSensile Medical AG+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Wearable Autoinjector Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Wearable Autoinjector Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Wearable Asthma Monitoring Device Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportWearable Artificial Kidney Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportWearable Ambulatory Monitoring Device Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportWearable Alcohol Biosensors Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportWearable ABPM Monitor Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportWeak Laser Oral 3D Camera Market
Market size, share, segmentation and regional forecast.
$912M market · 2025 base year
View reportWDXRF Spectrometer Market
Market size, share, segmentation and regional forecast.
$946M market · 2025 base year
View reportWBGT Heat Stroke Checkers Market
Market size, share, segmentation and regional forecast.
$521M market · 2025 base year
View reportWax Paper Medicine Pot Market
Market size, share, segmentation and regional forecast.
$397M market · 2025 base year
View reportWaving Shaker Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportWave Mixing Bioreactor Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportWavelength Swept Light Source Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.